Pooja M Dhupkar

  • Citations Per Year
Learn More
Primary and acquired resistance to anticancer antibody immunotherapies presents significant clinical challenges. Here, we demonstrate that proteolytic inactivation of cancer-targeting antibodies is an unappreciated contributor to cancer immune evasion, and the finding presents novel opportunities for therapeutic intervention. A single peptide bond cleavage(More)
Interleukin-2 (IL-2) is a very well-known cytokine that has been studied for the past 35 years. It plays a major role in the growth and proliferation of many immune cells such NK and T cells. It is an important immunotherapy cytokine for the treatment of various diseases including cancer. Systemic delivery of IL-2 has shown clinical benefit in renal cell(More)
4005. P299<lb>Phosphopeptides as novel tumor antigens in colorectal cancer<lb>Sarah A Penny, Jennifer G Abelin, Abu Z Saeed, Stacy A Malaker,<lb>Paisley T Myers, Jeffrey Shabanowitz, Stephen T Ward, Donald F<lb>Hunt, Mark Cobbold<lb>University of Birmingham, Birmingham, England, UK; University of<lb>Virginia, Charlottesville, VA, USA; Stanford University,(More)
Osteosarcoma (OS) is a primary bone malignancy, commonly culminating into aggressive pulmonary metastasis. Despite chemotherapy advances, the 5-year survival of pulmonary metastatic OS remains 25-30%. Immunotherapy is one of the promising novel approaches to target minimal residual and relapsed disease. Previously, we have demonstrated that Liposomal(More)
Crk (C10 regulator of kinase) adaptor proteins are highly expressed in many types of human cancers and often contribute to aggressive cancer phenotypes. Crk II, a member of CRK family, has been reported to regulate cell migration and metastasis in breast cancer cells. However, its role in other cancer types has not been reported. In this study, we(More)
  • 1